The identification of efficient predictive biomarkers for ICIs-based therapies, such as PD-1/PD-L1 inhibitors, is useful for optimizing treatment, particularly in NSCLC, as evidenced by the results of the analyzed studies. Here, PDCD1 is linked to non-small cell lung carcinoma.